MA62910A1 - Inhibiteurs de line-1 pour traiter des maladies du snc et des maladies systémiques - Google Patents
Inhibiteurs de line-1 pour traiter des maladies du snc et des maladies systémiquesInfo
- Publication number
- MA62910A1 MA62910A1 MA62910A MA62910A MA62910A1 MA 62910 A1 MA62910 A1 MA 62910A1 MA 62910 A MA62910 A MA 62910A MA 62910 A MA62910 A MA 62910A MA 62910 A1 MA62910 A1 MA 62910A1
- Authority
- MA
- Morocco
- Prior art keywords
- line
- inhibitors
- systemic diseases
- treat cns
- cns
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000009885 systemic effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163161050P | 2021-03-15 | 2021-03-15 | |
| PCT/US2022/020362 WO2022197689A1 (en) | 2021-03-15 | 2022-03-15 | Line-1 inhibitors to treat cns and systemic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA62910A1 true MA62910A1 (fr) | 2023-12-29 |
Family
ID=83321069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA62910A MA62910A1 (fr) | 2021-03-15 | 2022-03-15 | Inhibiteurs de line-1 pour traiter des maladies du snc et des maladies systémiques |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240173346A1 (https=) |
| EP (1) | EP4308237A4 (https=) |
| JP (1) | JP2024511973A (https=) |
| KR (1) | KR20230157430A (https=) |
| CN (1) | CN117355312A (https=) |
| AU (1) | AU2022237405A1 (https=) |
| BR (1) | BR112023018714A2 (https=) |
| CA (1) | CA3211369A1 (https=) |
| CL (1) | CL2023002746A1 (https=) |
| DO (1) | DOP2023000192A (https=) |
| IL (1) | IL305869A (https=) |
| MA (1) | MA62910A1 (https=) |
| MX (1) | MX2023010657A (https=) |
| UA (1) | UA130707C2 (https=) |
| WO (1) | WO2022197689A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12350264B2 (en) | 2019-11-22 | 2025-07-08 | Brown University | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder |
| WO2021102423A1 (en) | 2019-11-22 | 2021-05-27 | Brown University | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders |
| US20250170158A1 (en) * | 2022-02-22 | 2025-05-29 | Rome Therapeutics, Inc. | Methods of treating medical conditions using censavudine or a related compound |
| IL315480A (en) | 2022-03-15 | 2024-11-01 | Rome Therapeutics Inc | Compounds and methods for treating disease |
| WO2023178128A1 (en) * | 2022-03-15 | 2023-09-21 | Rome Therapeutics, Inc. | Methods of treating medical conditions using islatravir or a related compound |
| CA3246792A1 (en) * | 2022-03-30 | 2023-10-05 | Transposon Therapeutics, Inc. | NUCLEOSIDE LINE-1 INHIBITORS |
| WO2024129788A1 (en) * | 2022-12-13 | 2024-06-20 | Brown University | Small molecule inhibitors of the line-1 endonuclease domain |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2535045T3 (es) * | 2003-04-10 | 2015-05-04 | Vanderbilt Royalty Sub L.P. | Usos y composiciones para administración de capsaicina |
| EP2965760A1 (en) * | 2014-07-09 | 2016-01-13 | Université de Montpellier | Combination of antiretroviral agents for use in the prevention or treatment of chronic inflammatory diseases |
| CN105012305A (zh) * | 2015-07-24 | 2015-11-04 | 福建广生堂药业股份有限公司 | 拉米夫定及其药用盐治疗老年性黄斑部病变的用途 |
| RU2726210C2 (ru) * | 2018-12-27 | 2020-07-09 | Общество С Ограниченной Ответственностью "Пролонгированные Лекарства" | Комбинация противовирусных средств, набор и способ лечения на ее основе |
| EP3914604B1 (en) * | 2019-01-25 | 2026-03-04 | Brown University | Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders |
| TW202104210A (zh) * | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv蛋白酶抑制劑 |
-
2022
- 2022-03-15 KR KR1020237034983A patent/KR20230157430A/ko active Pending
- 2022-03-15 JP JP2023556734A patent/JP2024511973A/ja active Pending
- 2022-03-15 IL IL305869A patent/IL305869A/en unknown
- 2022-03-15 AU AU2022237405A patent/AU2022237405A1/en active Pending
- 2022-03-15 BR BR112023018714A patent/BR112023018714A2/pt unknown
- 2022-03-15 CN CN202280034771.5A patent/CN117355312A/zh active Pending
- 2022-03-15 MX MX2023010657A patent/MX2023010657A/es unknown
- 2022-03-15 US US18/550,498 patent/US20240173346A1/en active Pending
- 2022-03-15 WO PCT/US2022/020362 patent/WO2022197689A1/en not_active Ceased
- 2022-03-15 EP EP22772048.9A patent/EP4308237A4/en active Pending
- 2022-03-15 CA CA3211369A patent/CA3211369A1/en active Pending
- 2022-03-15 UA UAA202304574A patent/UA130707C2/uk unknown
- 2022-03-15 MA MA62910A patent/MA62910A1/fr unknown
-
2023
- 2023-09-14 CL CL2023002746A patent/CL2023002746A1/es unknown
- 2023-09-14 DO DO2023000192A patent/DOP2023000192A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022237405A1 (en) | 2023-11-02 |
| UA130707C2 (uk) | 2026-04-22 |
| WO2022197689A1 (en) | 2022-09-22 |
| KR20230157430A (ko) | 2023-11-16 |
| EP4308237A1 (en) | 2024-01-24 |
| DOP2023000192A (es) | 2024-02-29 |
| CL2023002746A1 (es) | 2024-04-05 |
| EP4308237A4 (en) | 2025-03-05 |
| US20240173346A1 (en) | 2024-05-30 |
| CN117355312A (zh) | 2024-01-05 |
| MX2023010657A (es) | 2023-09-21 |
| BR112023018714A2 (pt) | 2023-10-24 |
| IL305869A (en) | 2023-11-01 |
| CA3211369A1 (en) | 2022-09-22 |
| JP2024511973A (ja) | 2024-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA62910A1 (fr) | Inhibiteurs de line-1 pour traiter des maladies du snc et des maladies systémiques | |
| Gaginella et al. | Kinins as mediators of intestinal secretion | |
| Anthony et al. | Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS | |
| FR2445146A1 (fr) | Medicament a prise orale contenant une substance inhibitrice de l'inflammation et un ou plusieurs phospholipides | |
| TNSN94035A1 (fr) | Composition veterinaire | |
| TNSN07063A1 (fr) | Utilisations therapeutiques d'inhibiteurs de rtp801 | |
| Nielsen et al. | Mediators of inflammation in chronic inflammatory bowel disease | |
| TNSN04268A1 (fr) | UTILISATION D'INHIBITEURS CETP ET FACULTATIVEMENT D'INHIBITEURS DE HMG -CoA - REDUCTASE ET/OU D'AGENTS ANTI-HYPERTENSIFS | |
| HUP0301727A2 (hu) | Eljárás reumatoid artritisz kezelésére oldható mutáns CTLA4 molekula alkalmazásával | |
| MA29366B1 (fr) | Therapie antiangiogenique de maladie auto-immune chez des patients qui n'ont pas reagi a une therapie anterieure | |
| EP1140170A4 (en) | NEW SUBSTANCES AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF Ocular DISEASES | |
| NO20160655A1 (no) | Sammensetninger og fremgangsmåter for behandling av prostata- og andre cancere | |
| KR970704429A (ko) | 심혈관 질환의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of cardiovascular diseases) | |
| MA32056B1 (fr) | Suspension pharmaceutique orale contenant du paracetamol et de l'ibuprofene | |
| MA60154A1 (fr) | Inhibiteurs de line-1 pour traiter une maladie | |
| MA30413B1 (fr) | Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation | |
| WO2001054681A8 (en) | Composition for treatment of stress | |
| MA55199B1 (fr) | (n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques | |
| MA29218B1 (fr) | Nonadepsipeptides acyles sous forme de derives de lysobactine | |
| DE60334556D1 (de) | Chorionic gonadotropin zur Behandlung des chronischen Schmerzsyndroms des Beckens | |
| MA27690A1 (fr) | Composition pharmaceutique androgene et procede pour le traitement de la depression. | |
| MXPA03011502A (es) | Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer. | |
| Isordia-Salas et al. | The role of plasma high molecular weight kininogen in experimental intestinal and systemic inflammation | |
| WO2024112527A3 (en) | Methods for the treatment of thyroid eye disease | |
| WO1998041238A3 (en) | Methods and kits for treating and diagnosing leiomyomas |